1223TiP A randomized phase III study of first-line (1L) trastuzumab deruxtecan (T-DXd) with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair-proficient (pMMR), primary advanced or recurrent endometrial cancer (EC): DESTINY-Endometrial01/GOG-3098/ENGOT-EN24
B.M. Slomovitz(Mount Sinai Medical Center), P. Follana(Centre Antoine Lacassagne), Melissa A. Geller(Women's Cancer Center of Nevada), Elena Ioana Braicu(Charité - Universitätsmedizin Berlin), S. Ghamande(Augusta University Health), Ignacio A. Romero(Fundación Instituto Valenciano de Oncología), D. Black(Willis-Knighton Cancer Center), Hannelore Denys(Ghent University Hospital), A.N. Rodrigues(Eastern Cooperative Oncology Group), Randy C. Bowen(Royal United Hospital Bath NHS Trust), Stephen Welch(Western University), Annamaria Ferrero(A. O. Ordine Mauriziano di Torino), Antonella Savarese(Istituti di Ricovero e Cura a Carattere Scientifico), Anita Chudecka-Głaz(Pomeranian Medical University), K. K. Machado(AstraZeneca (Netherlands)), Cheng Zhang(AstraZeneca (Netherlands)), V. Makker(Memorial Sloan Kettering Cancer Center), M.R. Mirza(Copenhagen University Hospital)
Cited by 1Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis